Acorda Second Quarter 2020 Update: Webcast/Conference Call Scheduled for August 4, 2020
July 28 2020 - 7:00AM
Business Wire
Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference
call and webcast in conjunction with its second quarter 2020 update
and financial results on Tuesday, August 4 at 4:30 p.m. ET.
To participate in the Webcast/Conference call, please note there
is a new pre-registration process.
- To register for the Webcast, use the link below:
https://event.on24.com/wcc/r/2395726/EF22DB54EC8EDBD04D72B50A619971E1
- To register for the Conference Call, use the link below:
http://www.directeventreg.com/registration/event/5378839
**When registering please type your phone number with no
special characters**
Once you have registered, you will provided with
Webcast/Conference Call details. For the Webcast you will receive
an email 2 hours prior to the start of the call with the link to
join. The presentation will be available on the Investors section
of www.acorda.com.
A replay of the call will be available from 8:30 p.m. ET on
August 4, 2020 until 11:59 p.m. ET on September 3, 2020. To access
the replay, please dial (800) 585-8367 (domestic) or (416) 621-4642
(international); reference code 5378839. The archived webcast will
be available in the Investor Relations section of the Acorda
website at www.acorda.com.
About Acorda Therapeutics Acorda Therapeutics develops
therapies to restore function and improve the lives of people with
neurological disorders. INBRIJA® (levodopa inhalation powder) is
approved for intermittent treatment of OFF episodes in adults with
Parkinson’s disease treated with carbidopa/levodopa. INBRIJA is not
to be used by patients who take or have taken a nonselective
monoamine oxidase inhibitor such as phenelzine or tranylcypromine
within the last two weeks. INBRIJA utilizes Acorda’s innovative
ARCUS® pulmonary delivery system, a technology platform designed to
deliver medication through inhalation. Acorda also markets the
branded AMPYRA® (dalfampridine) Extended Release Tablets, 10
mg.
Forward-Looking Statements This press release includes
forward-looking statements. All statements, other than statements
of historical facts, regarding management's expectations, beliefs,
goals, plans or prospects should be considered forward-looking.
These statements are subject to risks and uncertainties that could
cause actual results to differ materially, including: we may not be
able to successfully market INBRIJA or any other products under
development; the COVID-19 pandemic, including related quarantines
and travel restrictions, and the potential for the illness to
affect our employees or consultants or those that work for other
companies we rely upon, could have a material adverse effect on our
business operations or product sales; our ability to raise
additional funds to finance our operations, repay outstanding
indebtedness or satisfy other obligations, and our ability to
control our costs or reduce planned expenditures and take other
actions which are necessary for us to continue as a going concern;
risks associated with complex, regulated manufacturing processes
for pharmaceuticals, which could affect whether we have sufficient
commercial supply of INBRIJA to meet market demand; third party
payers (including governmental agencies) may not reimburse for the
use of INBRIJA or our other products at acceptable rates or at all
and may impose restrictive prior authorization requirements that
limit or block prescriptions; competition for INBRIJA, AMPYRA and
other products we may develop and market in the future, including
increasing competition and accompanying loss of revenues in the
U.S. from generic versions of AMPYRA (dalfampridine) following our
loss of patent exclusivity; the ability to realize the benefits
anticipated from acquisitions, among other reasons because acquired
development programs are generally subject to all the risks
inherent in the drug development process and our knowledge of the
risks specifically relevant to acquired programs generally improves
over time; the risk of unfavorable results from future studies of
INBRIJA (levodopa inhalation powder) or from our other research and
development programs, or any other acquired or in-licensed programs
; the occurrence of adverse safety events with our products; the
outcome (by judgment or settlement) and costs of legal,
administrative or regulatory proceedings, investigations or
inspections, including, without limitation, collective,
representative or class action litigation; failure to protect our
intellectual property, to defend against the intellectual property
claims of others or to obtain third party intellectual property
licenses needed for the commercialization of our products; and
failure to comply with regulatory requirements could result in
adverse action by regulatory agencies.
These and other risks are described in greater detail in our
filings with the Securities and Exchange Commission. We may not
actually achieve the goals or plans described in our
forward-looking statements, and investors should not place undue
reliance on these statements. Forward-looking statements made in
this press release are made only as of the date hereof, and we
disclaim any intent or obligation to update any forward-looking
statements as a result of developments occurring after the date of
this press release.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20200728005080/en/
Tierney Saccavino (917) 783-0251 tsaccavino@acorda.com
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Aug 2024 to Sep 2024
Acorda Therapeutics (NASDAQ:ACOR)
Historical Stock Chart
From Sep 2023 to Sep 2024